GlaxoSmithKline Pharmaceuticals Share Price Target 2026: Expert Forecast, Growth Catalysts and Key Risks

The GlaxoSmithKline Pharmaceuticals share price target for 2026 stands at Rs 2200 as per the latest analyst forecast, implying 22 percent upside from the current market price of Rs 1800. Investors tracking the GlaxoSmithKline Pharmaceuticals share price target 2026 need to understand the full picture including growth catalysts, FY27 earnings timeline, key risks, and the bull vs bear case scenarios. This article covers every dimension of the GlaxoSmithKline Pharmaceuticals share price target thesis updated April 2026.

Click Here to Get Free Investment Predictions on Univest

Track live GlaxoSmithKline Pharmaceuticals price, FII or DII flows and analyst targets on the Univest Screener.

GlaxoSmithKline Pharmaceuticals Company Overview

Tap to Access Best Research on Univest

GlaxoSmithKline Pharmaceuticals (NSE: GLAXO) is a listed company in India’s Pharma sector with a market capitalisation of Rs 30420 crore. At CMP Rs 1800 against a 52 week range of Rs 1610 to Rs 2050, the stock currently offers meaningful upside to the analyst price forecast of Rs 2200. For more share price target analysis, visit Univest Blogs.

Parameter	Value
NSE Ticker	GLAXO
Sector	Pharma
CMP April 2026	Rs 1800
52 Week High	Rs 2050
52 Week Low	Rs 1610
Market Cap	Rs 30420 crore
Trailing P/E	34x
12M Analyst Price Forecast	Rs 2200
Bull Case Target	Rs 2600
Bear Case Target	Rs 1400

Why Analysts Set the GlaxoSmithKline Pharmaceuticals Share Price Target at Rs 2200 for 2026

FY27 Earnings Delivery and Revenue Acceleration

FY27 is the key year where analysts expect GlaxoSmithKline Pharmaceuticals to deliver meaningful PAT growth. This is the primary variable that bridges the gap between the current CMP of Rs 1800 and the GlaxoSmithKline Pharmaceuticals share price target 2026 of Rs 2200. Analysts project 15 to 20 percent PAT growth in FY27. Track Q4 results live on the Univest Screener.

Revenue scale-up from new product launches

Revenue scale-up from new product launches is a key growth driver that analysts highlight in supporting the GlaxoSmithKline Pharmaceuticals share price target of Rs 2200. The Pharma sector is expanding at 12 to 18 percent annually, and GlaxoSmithKline Pharmaceuticals is well-positioned to capture a rising share. Discover top Pharma stocks on the Univest Screener.

Margin expansion through operating leverage

Margin expansion through operating leverage provides an additional lever that can help GlaxoSmithKline Pharmaceuticals exceed analyst projections and potentially push the stock toward the bull case target of Rs 2600. Compare GlaxoSmithKline Pharmaceuticals with sector peers on the Univest Screener.

RBI Rate Cut Cycle and Lower Cost of Capital

India’s rate cut cycle that commenced in 2026 reduces GlaxoSmithKline Pharmaceuticals’s borrowing costs and stimulates end-market demand, supporting the GlaxoSmithKline Pharmaceuticals share price target 2026 of Rs 2200.

Union Budget 2026-27 Policy Support

Budget 2026-27 capex continuity and PLI scheme extensions create a constructive backdrop for GlaxoSmithKline Pharmaceuticals’s Pharma business, directly supporting the GlaxoSmithKline Pharmaceuticals share price target 2026 bull case of Rs 2600.

Bull Case, Base Case and Bear Case for GlaxoSmithKline Pharmaceuticals Share Price Target

Scenario	Target	Key Assumption
Bull Case	Rs 2600	FY27 revenue growth exceeds 25 percent, margin expansion of 200 bps, sector re-rating
Base Case Forecast	Rs 2200	FY27 revenue growth of 15 to 18 percent, stable margins, current P/E sustained
Bear Case	Rs 1400	Revenue growth disappoints below 10 percent, margin pressure, valuation de-rating

For live tracking of GlaxoSmithKline Pharmaceuticals analyst price targets and ratings, use the Univest Screener.

Key Risks to the GlaxoSmithKline Pharmaceuticals Share Price Target

Earnings Miss Risk

If GlaxoSmithKline Pharmaceuticals reports quarterly earnings below expectations, the GlaxoSmithKline Pharmaceuticals share price target will likely face downward revision. Watch Q4 FY26 results closely on Univest Screener.

Macro and Global Headwinds

The US 26 percent reciprocal tariff announcement of April 2026 has created global macro uncertainty that adds near-term risk to the GlaxoSmithKline Pharmaceuticals share price target 2026 timeline.

Sector-Specific Risks

Regulatory changes, input cost volatility, and competitive intensity in the Pharma space could pressure margins and delay realisation of the GlaxoSmithKline Pharmaceuticals share price target of Rs 2200.

FII Outflows

Continued FII selling in Indian equities could suppress the valuation multiples needed for GlaxoSmithKline Pharmaceuticals to reach its analyst price forecast of Rs 2200 within the 12 month horizon.

GlaxoSmithKline Pharmaceuticals Financial Snapshot FY25 to FY27

Metric	FY25 Actual	FY26 Estimate	FY27 Estimate
Revenue (Rs Cr)	Refer NSE filing	Refer NSE filing	Refer NSE/BSE filing
EBITDA Margin	Refer NSE filing	Refer NSE filing	Expected expansion
PAT (Rs Cr)	Refer NSE filing	Refer NSE filing	15 to 20 percent growth
Market Cap	Rs 30420 crore	Higher at 52W peak	Tracks price movement
P/E Ratio	34x	Current level	Target implies re-rating
52 Week High / Low	Rs 2050 / Rs 1610

If you want to track GlaxoSmithKline Pharmaceuticals financial metrics, analyst ratings and peer comparisons in real time, check the Univest Screener for live data.

Technical Outlook for GlaxoSmithKline Pharmaceuticals Share Price

GlaxoSmithKline Pharmaceuticals is trading at Rs 1800, currently attempting to build a base above its 52 week low of Rs 1610. The stock needs to reclaim its 200 day moving average to confirm a meaningful recovery trend. The GlaxoSmithKline Pharmaceuticals share price target of Rs 2200 set by analysts assumes fundamental delivery over the next 12 months rather than near-term price action. Download the Univest iOS App or Univest Android App to track GlaxoSmithKline Pharmaceuticals live price and set alerts.

Conclusion

The GlaxoSmithKline Pharmaceuticals share price target 2026 of Rs 2200 reflects analyst conviction on FY27 earnings delivery, structural sector tailwinds, and the favourable domestic macro environment. The bull case of Rs 2600 is achievable if the company executes above expectations. Investors should monitor quarterly earnings, FII ownership trends and management commentary closely. For real-time tracking and research, use the Univest Screener.

This article is for informational and educational purposes only and is not investment advice. Univest is SEBI registered (INH000013776). Please consult a SEBI registered financial advisor before making any investment decision.

Frequently Asked Questions

What is the GlaxoSmithKline Pharmaceuticals share price target for 2026?

The GlaxoSmithKline Pharmaceuticals share price target for 2026 is Rs 2200 as per the analyst price forecast, implying 22 percent upside from the current price of Rs 1800. The bull case target is Rs 2600 and the bear case is Rs 1400.

Is GlaxoSmithKline Pharmaceuticals a good buy at Rs 1800?

At Rs 1800, GlaxoSmithKline Pharmaceuticals trades at a trailing P/E of 34x and offers potential upside to the analyst price forecast of Rs 2200. Whether it is a good buy depends on your investment horizon and risk appetite. Always consult a SEBI registered financial advisor.

What is the 52 week high and low of GlaxoSmithKline Pharmaceuticals?

The 52 week high of GlaxoSmithKline Pharmaceuticals is Rs 2050 and the 52 week low is Rs 1610. The current CMP of Rs 1800 positions the stock at a meaningful discount to its peak, which is factored into the analyst GlaxoSmithKline Pharmaceuticals share price target 2026.

What sector does GlaxoSmithKline Pharmaceuticals belong to?

GlaxoSmithKline Pharmaceuticals belongs to India’s Pharma sector and trades on NSE with the ticker GLAXO. Track the entire Pharma sector on the Univest Screener.

What is the bull case for GlaxoSmithKline Pharmaceuticals share price?

The bull case for GlaxoSmithKline Pharmaceuticals share price is Rs 2600, which assumes revenue growth exceeding 25 percent in FY27, margin expansion of 200 basis points, and a positive re-rating of the Pharma sector. This scenario requires strong execution and supportive macro conditions.

What are the key risks to the GlaxoSmithKline Pharmaceuticals share price target?

Key risks include earnings miss in upcoming quarters, continued FII selling, regulatory headwinds in the Pharma sector, raw material cost volatility, and global macro uncertainty driven by the US tariff environment. These risks could push the stock toward the bear case of Rs 1400.

Recent Article

Heritage Foods Share Price Target 2026: Expert Forecast, Growth Catalysts and Key Risks

ICICI Lombard General Insurance Share Price Target 2026: Expert Forecast, Growth Catalysts and Key Risks

Indoco Remedies Share Price Target 2026: Expert Forecast, Growth Catalysts and Key Risks

Niva Bupa Health Insurance Share Price Target 2026: Expert Forecast, Growth Catalysts and Key Risks

Gujarat Fluorochemicals Share Price Target 2026: Expert Forecast, Growth Catalysts and Key Risks